

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cryofocus Medtech (Shanghai) Co., Ltd.

康澧生物科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6922)

VOLUNTARY ANNOUNCEMENT

NMPA APPROVAL FOR THE REGISTRATION CHANGE OF DISPOSABLE CRYOPROBE OF CRYOADHESION SYSTEM

This announcement is made by Cryofocus Medtech (Shanghai) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders of the Company and potential investors about the latest business development of the Group.

The Company is pleased to announce that, following the grant of approval by the National Medical Products Administration of the People's Republic of China (國家藥品監督管理局) (the “**NMPA**”) to the other component of the Group's Cryoadhesion System (the “**Cryoadhesion System**”), which is one of the Group's respiratory interventional products, namely, disposable cryoprobe (一次性使用冷凍探頭) on January 9, 2024, the registration change of disposable cryoprobe to cryoprobe (冷凍探頭) was granted approval by the NMPA on August 5, 2025.

With this approval granted by the NMPA, the commercialization pathway for the Cryoadhesion System will be further optimized. The cryoprobe, featuring both disposable and re-sterilizable product characteristics, will address relevant indications more comprehensively.

The Cryoadhesion System, which employs subcritical refrigeration technology (亞臨界製冷技術) and heat transfer with controlled pressure technology (控壓傳熱技術) for rapid cryoadhesion, will be used for the cryoremoval of foreign bodies, mucous, blood clots and necrotic tissues in the airway, as well as for the cryobiopsy of bronchial and lung tissues.

THE COMPANY CANNOT GUARANTEE THE FUTURE PROSPECTS OF THE CRYOADHESION SYSTEM. SHAREHOLDERS OF THE COMPANY AND THE POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By Order of the Board
Cryofocus Medtech (Shanghai) Co., Ltd.
Mr. LI Kejian
Chairman of the Board

Hong Kong, August 7, 2025

As at the date of this announcement, the Board comprises Mr. LI Kejian, Mr. ZHU Jun and Mr. LIU Wei as executive Directors, Mr. LV Shiwen and Mr. ZHAO Chunsheng as non-executive Directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive Directors.